Design Therapeutics Inc
NASDAQ:DSGN

Watchlist Manager
Design Therapeutics Inc Logo
Design Therapeutics Inc
NASDAQ:DSGN
Watchlist
Price: 4.47 USD 1.36%
Updated: May 20, 2024

Design Therapeutics Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Design Therapeutics Inc
Total Current Liabilities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Design Therapeutics Inc
NASDAQ:DSGN
Total Current Liabilities
$9.6m
CAGR 3-Years
61%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$41.5B
CAGR 3-Years
9%
CAGR 5-Years
24%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$13B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
8%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$19.7B
CAGR 3-Years
15%
CAGR 5-Years
9%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$3.8B
CAGR 3-Years
25%
CAGR 5-Years
28%
CAGR 10-Years
26%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.6B
CAGR 3-Years
4%
CAGR 5-Years
19%
CAGR 10-Years
28%

See Also

What is Design Therapeutics Inc's Total Current Liabilities?
Total Current Liabilities
9.6m USD

Based on the financial report for Dec 31, 2023, Design Therapeutics Inc's Total Current Liabilities amounts to 9.6m USD.

What is Design Therapeutics Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
61%

Over the last year, the Total Current Liabilities growth was -11%. The average annual Total Current Liabilities growth rates for Design Therapeutics Inc have been 61% over the past three years .